Search results

I think they also relied on the UK BioBank, but it was mainly based on DecodeME, so I wouldn't call it replicating in independent datasets. Here's the bit about overlap with the 8 original DecodeME loci, which is based on SNPs in double refined signatures, which were created based on DecodeME.

It seems like the main result is based on testing significance within each group separately and comparing p-values. This isn't how you demonstrate that one group differs significantly from another group. Also, there are different numbers of people in each group: If we assume each group might...

Many of the same authors as the recent preprint: Evidence of Accumulating Neurophysiologic Dysfunction in Persistent Post-COVID Fatigue, 2025, Germann et al

Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue (PAuSing-pCF) [Line breaks added] Abstract Even mild SARS-CoV-2 infection can lead to post-COVID syndrome, 70% of such patients have post-COVID fatigue (pCF). Many physiological abnormalities observed in pCF could be...

The results section says: But the discussion gives a different hazard ratio for 3 to 6 months. I'm not sure if this is referring to something else. And the discussion talks about a figure for mortality that I can't find in the results or supplementary file, and I don't see anything about...

“We need to be believed": A qualitative interview study on the Hertfordshire (UK) Long Covid and Physical Activity Study [Line breaks added] Background The Covid-19 pandemic has led to the emergence of Long Covid, a complex multisystem condition characterised by persistent symptoms lasting...

Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 [Line breaks added] Abstract The guidelines presented herewith are based on the “Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 (PASC)” published in Infection & Chemotherapy in...

SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients Background Long COVID presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors...

I'm becoming more hopeful that this could be useful as I add more findings from different studies. I've saved 43 studies so far. I just added the 19 genes highlighted in the text of a 2016 GWAS (Schlauch et al), then did a search to see if any of those genes had been saved for any other studies...

Long-Term Health Effects of COVID-19 in Tunisia, 2020–2021 Background Some patients suffer from persistent symptoms following a COVID-19 infection, referred to as long COVID. The aims of the study were to estimate the prevalence of long COVID and study its determinants in Tunisia. Methods...

Russian journal. One author. There's no registration on ClinicalTrials.gov with that number. It refers to a figure 1, but I don't see any figures. That seems like a very significant result [Edit: I just mean low p-value], assuming there was good blinding. Is it because so many of them are...

Impact of Micronutrients on Recovery and Rehabilitation Strategies in Long COVID Saidov F.A. Abstract Long COVID, or post-acute COVID-19 syndrome, is characterized by persistent symptoms and functional impairment following acute SARS-CoV-2 infection. Micronutrients such as vitamins and trace...

Looking at data from Chinese hospitals to try to make a model that predicts methylprednisolone effectiveness. Based on preliminary analysis, they selected these variables for training several types of machine learning models: They trained 6 types of machine learning models, and based on...

An Interpretable Machine Learning Model for Predicting the Effectiveness of Low-Dose Methylprednisolone in Treating Long COVID: A Retrospective Study [Line breaks added] Abstract Long COVID is a chronic, multisystem disease with limited response to conventional treatments. While low-dose...

Noting that this is a follow-up to a previous paper from the same author on the same data: Cerebrospinal fluid metabolomics, lipidomics and serine pathway dysfunction in [ME/CFS], 2025, Baraniuk

This paper says: 124 is that other paper. It does appear that the other paper has other results not included in this one, and the wording is changed throughout the paper. I haven't read either of these in detail, but just as a rough measure, there are 1782 words in this paper's Results...

They talk about results of administering a replacement for vasopressin. I made a thread for an older study of desmopressin for POTS: Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome, 2012, Coffin et al

This is from 2012. Posting because desmopressin is a synthetic version of vasopressin, and a recent study found low vasopressin in ME/CFS: Low Vasopressin In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, 2025, Endocrine Practice Edit: See also a small uncontrolled trial of desmopressin...

Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome Background Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance with an excessive increase in heart rate on standing, and many patients...

I see there are about 22 out of the 115 genes that are primarily brain genes (high expression in brain, low expression everywhere else) based on the heatmap. None of the other tissues really stand out as having their own specific set of genes.